Immunology and Biotherapies

Pamlico Biopharma, Inc. was founded around human monoclonal antibody therapeutics and technologies from the OMRF and from Emory University. PAMLICO focuses on human monoclonal antibody therapeutics for human pathogens, cancer and autoimmune diseases. The lead project will address pneumonia caused by S pneumoniae. Pneumococcal pneumonia remains a major cause of morbidity and mortality worldwide. The magnitude of the clinical challenge is likely to increase as multiple strains of the bacteria have developed resistance to multiple antibiotics. PAMLICO’s lead project is a monoclonal antibody therapy for severe (PSI -V) community-acquired pneumonococcal pneumonia, which has a 20-35% mortality rate that has remained constant for 2 decades. The therapeutic goal is to reduce mortality by 20%, which the company anticipates demonstrating in a superiority study compared to standard care alone.

Via Krishan Maggon